Physiomics Expands into Rheumatoid Arthritis with New UK Contract

Physiomics ( (GB:PYC) ) has issued an announcement.

Physiomics plc has secured a contract with a new UK client to apply population Pharmacokinetic modelling techniques to Phase 1 data for a small molecule aimed at treating rheumatoid arthritis. This £67,500 project, expected to conclude in three months, marks Physiomics’ first venture into rheumatoid arthritis and represents a strategic expansion into new therapeutic areas. The contract also includes a Master Service Agreement for potential future projects, highlighting the company’s growing client base and expertise in supporting advanced-stage development programs.

Spark’s Take on GB:PYC Stock

According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.

Physiomics’ stock score is primarily impacted by significant financial instability, including declining revenues and negative profit margins. Technical indicators reinforce a bearish outlook. While recent corporate events suggest potential growth pathways, current valuation issues and financial challenges remain significant obstacles.

To see Spark’s full report on GB:PYC stock, click here.

More about Physiomics

Physiomics plc is a prominent company in the field of mathematical modelling, data science, and biostatistics, focusing on the development of new therapeutics and personalized medicine solutions. The company leverages expertise in Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics to assist biotech and pharma companies in optimizing their drug development processes. Physiomics has contributed to over 100 commercial projects, working with notable clients such as Merck KGaA, Astellas, and Bicycle Therapeutics.

Average Trading Volume: 7,097,380

Technical Sentiment Signal: Sell

Current Market Cap: £1.46M

For detailed information about PYC stock, go to TipRanks’ Stock Analysis page.